ReviewGenes & diseases2026
Molecular mastery: Harnessing DNA technology for disease prevention.
Review in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in DNA technology are revolutionizing the landscape of illness prevention, providing new opportunities to combat hereditary abnormalities and chronic diseases before they manifest. CRISPR-Cas9 gene editing, epigenetic alterations, somatic cell genome editing, and RNA-based therapies are all significant advancements in this field. These techniques enable precise changes to DNA and gene expression, potentially preventing a wide range of illnesses at their genetic origins. The following discussion delves into the transformative potential of these technologies. CRISPR-Cas9 is notable for its precision in fixing defective genes, offering promise for avoiding diseases, such as cystic fibrosis and sickle cell anemia. Epigenetic modifications caused by environmental factors are also opening up new avenues for preventing chronic illnesses and malignancies. Furthermore, somatic cell genome editing is a potential, ethically viable strategy as it targets non-reproductive cells, preventing heritable genetic alterations. Along with these developments, RNA-based therapies are emerging as a new avenue for disease prevention. This paper will explore each of these advancements, their applications, and the ethical and technical challenges involved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.